Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/1999
11/04/1999WO1999055663A1 Inhibitors of impdh enzyme
11/04/1999WO1999055388A1 Substituted porphyrins
11/04/1999WO1999055381A1 Method and process for establishment of stage specific expression and characterization of proteins based on microbial or human genomic sequence data
11/04/1999WO1999055378A1 Method of treating endotoxemia
11/04/1999WO1999055377A2 Polyol-ifn-beta conjugates
11/04/1999WO1999055375A1 Stable mitoxantron solutions
11/04/1999WO1999055372A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
11/04/1999WO1999055370A1 Methods for reducing hiv viral load by administering gm-csf and antiretroviral agents
11/04/1999WO1999055366A1 Chimeras of hepatitis c virus and bovine viral diarrhea virus
11/04/1999WO1999055348A2 Stabilised virus preparation
11/04/1999WO1999055347A2 Treatment of papilloma virus infection using a mycobacterium
11/04/1999WO1999055342A1 Therapeutic anti-cold agent containing isomalt as an active ingredient
11/04/1999WO1999055312A2 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
11/04/1999WO1999055162A1 Method for the treatment of viral disease
11/04/1999WO1999046372A3 Ribozymes capable of inhibiting the expression of the ccr5 receptor
11/04/1999WO1999045104A3 Purification of virus preparations
11/04/1999WO1999040921A3 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
11/04/1999WO1999033981A3 Human signal peptide-containing proteins
11/04/1999WO1999024589A3 Lysozym-analogous proteins and peptide having an anti-microbial activity, production of the same and use thereof
11/04/1999WO1999019481A3 Mammalian genes involved in viral infection and tumor suppression
11/04/1999WO1998027073A8 Asymmetric synthesis of benzoxazinones
11/04/1999WO1997049812A3 Process for extracting and purifying recombinant, non-lipidised osp-protein
11/04/1999CA2565375A1 Polyol-ifn-beta conjugates
11/04/1999CA2330564A1 Quinolones used as mrs inhibitors and bactericides
11/04/1999CA2330563A1 Therapeutic anti-cold agent containing isomalt as an active ingredient
11/04/1999CA2330451A1 Polyol-ifn-beta conjugates
11/04/1999CA2330428A1 Treatment of mastitis
11/04/1999CA2330391A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
11/04/1999CA2330387A1 Treatment of papilloma virus infection using a mycobacterium
11/04/1999CA2330304A1 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
11/04/1999CA2330111A1 Phosphonic acid diester derivatives and their use in lowering blood glucose level and treating diabetes
11/04/1999CA2330086A1 Chimeras of hepatitis c virus and bovine viral diarrhea virus
11/04/1999CA2330033A1 Method of treating endotoxemia
11/04/1999CA2329920A1 Methods for reducing hiv viral load by administering gm-csf and antiretroviral agents
11/04/1999CA2329897A1 Polysaccharide-antigen conjugates
11/04/1999CA2329434A1 Pharmaceutically available protoberberine salts derivatives, and protoberberine derivatives and salts thereof
11/04/1999CA2327317A1 Polynucleotides isolated from skin cells and methods for their use
11/04/1999CA2327178A1 Host-encoded protein expressed on marek's disease (mdv)-infected cells and antibody thereto
11/04/1999CA2326695A1 Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis c virus infection
11/04/1999CA2326376A1 Polyepitope carrier protein
11/04/1999CA2326375A1 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
11/04/1999CA2325055A1 Vaccines containing recombinant pilin against neisseria gonorrhoeae or neisseria meningitidis
11/03/1999EP0953648A2 Viral defective vaccine produced by transcomplementing cell line
11/03/1999EP0953642A1 Antigenic protein originating in infectious laryngotracheitis virus
11/03/1999EP0953641A2 Polynucleotide molecules encoding neospora proteins
11/03/1999EP0953630A1 Transesterification products of corn oil and glycerol and their use in pharmaceutical compositions
11/03/1999EP0953570A1 Fluorinated cephalosporin antibiotics and their use for the treatment of mastitis
11/03/1999EP0953351A2 Medicaments containing, as the main ingredient, allogenic activated-CD4+ cells and method for producing the same
11/03/1999EP0952986A1 Antimicrobially active polypeptides
11/03/1999EP0952985A1 Broad spectrum pyrogenic exotoxins antagonists and vaccines
11/03/1999EP0952846A1 Prolactin as a vaccine adjuvant
11/03/1999EP0639081B1 Vaccine compositions for mucosal delivery
11/03/1999CN1234078A Compositions and method for treating viral infections
11/03/1999CN1234071A Keratinocyte grouth factor -2(KGF-2 or fibroblast growth factor-12, FGF-12)
11/03/1999CN1234036A Crystalline substance of cefditoren pivoxyl and prodn. of same
11/03/1999CN1234031A Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the prodn. of tumor necrosis factor (TNF)
11/03/1999CN1233958A Use of combination of amoxycillin and clavulanate in mfg. medicament for treatment drug-resistant streptococcus pneumonia
11/03/1999CN1233474A Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections
11/02/1999US5977381 Process for making 3-amino-pyrolidine derivatives
11/02/1999US5977373 Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
11/02/1999US5977337 The nucleic acid molecule may be used in the diagnosis of infection.
11/02/1999US5977332 Oligonucleotides having 2'-ether groups
11/02/1999US5977328 Reacting a carbohydrate having at least one monosaccharide unit with a partially protected starch, removing the protecting groups, and purifying product; bactericides, parasiticides; preventing formation of/or disrupting biofilms
11/02/1999US5977296 Chiral peptide nucleic acid monomers and oligomers
11/02/1999US5977169 Substituted tetronic acids useful for treating HIV and other retroviruses
11/02/1999US5977122 Antiinflammatory, antiallergens, tumor necorsis factor inhibitor
11/02/1999US5977108 Leukemia
11/02/1999US5977103 Substituted imidazole compounds
11/02/1999US5977097 1-methylcarbapenem derivatives
11/02/1999US5977085 Vectors carrying coding sequence for the SpsB protein of Staphylococcus aureus
11/02/1999US5977083 Vascular disorders; kidney disorders; hypotensive agents
11/02/1999US5977067 Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them
11/02/1999US5977063 Alkylated hexapeptides
11/02/1999US5977062 Active against antibiotic resistant bacteria
11/02/1999US5977061 Viricide against dna viruses
11/02/1999US5976884 Methods for quantifying photoreactions in light activated materials
11/02/1999US5976849 Human E3 ubiquitin protein ligase
11/02/1999US5976834 cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor
11/02/1999US5976785 Competitive assays for determining the effectiveness of a human immunodeficiency virus type 2 (HIV-2) antiviral agent, employing peptides and proteins of HIV-2
11/02/1999US5976781 Diagnosing malaria by mixing blood with enzyme inhibitor, determining enzyme activity, comparing to control sample; plasmodium enzyme is more sensitive to inhibition so deactivation indicates disease
11/02/1999US5976558 Silicone-containing derivatives of salicylic acid which have desquamating properties
11/02/1999US5976552 Virus vaccines
11/02/1999US5976544 Polypeptides and vaccines for Bordetellapertussis and method of use
11/02/1999US5976542 Bacterial enzymes as targets for antibiotic therapy and as bacterial vaccines.
11/02/1999US5976541 Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
11/02/1999US5976537 A previously unknown disease of pigs, prrs was recognized for the first time in the united states in north carolina in 1987. from there, it quickly spread throughout all of the major swine producing areas of north america.
11/02/1999US5976536 Neisseria mutants, lipooligosaccharides and immunogenic compositions
11/02/1999US5976525 Can be used to produce protective vaccines, such as inactivated whole cell or subunit vaccines, or for diagnostic purposes such as for the production of antibodies and detection of pathogenic enteric bacteria or to produce
11/02/1999US5976492 Radioactive phosphorus labeled proteins for targeted radiotherapy
11/02/1999CA2160689C New method of treatment
10/1999
10/30/1999CA2270754A1 Selection process for bacterial strain
10/28/1999WO1999054954A2 Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections
10/28/1999WO1999054735A1 Improved immunodiagnostic assays using reducing agents
10/28/1999WO1999054481A1 Mutant having uracil phosphoribosyl transferase activity
10/28/1999WO1999054469A1 B-cell growth factor related protein
10/28/1999WO1999054457A1 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
10/28/1999WO1999054351A1 Edg family gene, human h218
10/28/1999WO1999054341A1 Enhanced antisense modulation of icam-1
10/28/1999WO1999054326A1 Dihydropyrimidines
10/28/1999WO1999054323A1 Production of furanones
1 ... 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 ... 1798